# Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung

> **NCT01872403** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** nanoparticle albumin-bound paclitaxel/carboplatin

## Key facts

- **NCT ID:** NCT01872403
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-10
- **Primary completion:** 2015-06
- **Final completion:** 2017-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2013-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01872403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01872403, "Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01872403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*